| Methods |
4‐ to 5‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐110 mm Hg at weeks 3 and 4 of run‐in, and two BP readings for two visits could not differ by > 8 mm Hg; an optional visit was permitted at week 5 and the mean DBP values at weeks 4 and 5 were then used to determine eligibility; 8‐week double‐blind treatment |
| Participants |
All patients: n=683(444 males,239 females); mean age=55.0(10.5) years; baseline sitting SBP=151(14.7) mm Hg, DBP=100(4.2) mm Hg |
| Interventions |
Irbesartan 37.5 mg once daily;
Irbesartan 100 mg once daily;
Irbesartan 300 mg once daily;
Placebo;
taken between 6 AM and 10 AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; baseline SD reported; BP data from Table 2, p. 801; Jadad score=4; funding= Bristol‐Myers Squibb |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
